Good morning, ladies and gentlemen, and welcome to the Q1 2017 ReWalk Robotics Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to your host, Ms. Ilanit Allen. You may begin.

Thank you, Kirsten. Good morning, and welcome to ReWalk Robotics First Quarter 2017 Earnings Call. This is Ilanit Allen of In-Site Communications, Investor Relations for ReWalk. With me on today's call are Larry Jasinski, Chief Executive Officer; and Kevin Hershberger, Chief Financial Officer of ReWalk. This morning, the company issued a press release detailing financial results for the 3 months ended March 31, 2017. This can be accessed through the Investor Relations section of the ReWalk website at rewalk.com, and you can also access the web cast of this call from there. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to ReWalk management as of today and involve risks and uncertainties, including those noted in this morning's press release and ReWalk's filings with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. ReWalk specifically disclaims any intent or obligation to update these forward-looking statements, except as required by law. A telephone replay of the call will be available shortly after completion of this call for the next 2 weeks. You'll find the dial-in information in today's press release. The archived webcast will be available for one year on the company's website, rewalk.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on May 4, 2017. Since then, ReWalk may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings. And with that, I'll turn the call over to ReWalk's CEO, Larry Jasinski.

Thank you, llanit. Good morning, everyone, and thank you for joining us. We had an excellent first quarter, with record revenue of $2.5 million, including a record 14 favorable commercial coverage decisions, with a total of 37 ReWalk placements. We made meaningful progress with the VA and with commercial payers on the reimbursement front, and we moved closer to a design freeze on our stroke product. As we indicated in our last call, our focus is on working with the VA to qualify and expedite processing of veterans via the co-op study and the SOP program; securing broader reimbursement coverage in the U.S. and Germany with both corporate entities and commercial providers; and finalizing the design, initial production, and clinical study setup to support regulatory filings and late 2018 commercialization of the restore soft exoskeleton product for stroke patients. I'm pleased to report on all of these fronts, we had encouraging and demonstrable results that show the promise and growth that is developing with this new industry. We continue to make progress in building our business with the VA. During the first quarter, the VA placed an order of 28 units for its co-op study, of which 20 units were shipped in Q1. This purchase will allow each of the 10 co-op study sites to be fully active and recruiting subjects by midyear. As a reminder, this multi-year study will evaluate 160 subjects in two cohorts: 80 using the ReWalk exoskeleton and 80 in the control arm. The study design is focused on home and community use, and is the first randomized and most comprehensive study being conducted on the benefits of using exoskeleton technology in the world today. The study is making meaningful progress, with the first six study sites recruiting 25 users to date. 14 were in the…

Thanks, Larry. Q1 revenue was $2.5 million compared to $2.1 million in the prior year quarter, and included 14 favorable commercial coverage decisions -- 5 in the U.S. and 9 in Germany. We placed a total of 37 units, of which 26 were in the U.S., consisting of 20 for the VA study, one for a veteran covered under the VA SOP, and 5 covered commercial insurance. The remaining 11 units were placed in Europe. As I've done in the past, I'd like to give you some additional detail on our rental units. We had 10 rent-to-purchase units placed during the first quarter, including one with the VA, and we had five previously-rented units that were converted to purchases. We currently have 26 open trials, including 21 active rentals and 5 claimed that have completed their trial period and are awaiting insurance decisions. Gross margin improved to 42% for Q1, driven by increased volume, conversion of rental units to purchases, favorable geographic mix impacting our ASPs, and lower product cost. Total operating expenses for the quarter were $6.7 million compared to $6.9 million in the prior year period. As we discussed on the last call, we have implemented initiatives to reduce operating expenses, the full impact of which will become more visible throughout the year. Net loss for the quarter was $6.4 million compared to a net loss of $6.9 million in the first quarter of 2016, and we ended the quarter with $17.1 million in cash. With that, I'd like to open the call for questions. Operator, please go ahead with the instructions.

Thank you, ladies and gentlemen, [Operator Instructions] Your first question comes from the line of Matt O'Brien from Piper Jaffray. Your line is open.

Hi good morning. This is J.P. on for Matt. Thanks for taking the question. Congrats on the quarter. I wanted to start first with in Germany, it seems like you're seeing a lot of good uptake there. How much of that is from, I think it was last summer you had the German Social Court ruling. And so, maybe talk a little bit about that tailwind that's provided for you guys. And then just in terms of patient awareness building now that it's getting more and more often covered in Germany, are you seeing more patients kind of funnel into the pipeline, and should we think about that as a good precedence for the U.S.?

Clearly, those court cases last summer did have an impact because the groups that we're talking to on contractual and policy side now have many cases that are pending, and they're also some of the same groups that have done the large number of rentals we had in the first quarter here. So the pattern is what we hoped it would be in Germany, and we believe the output at the end, as some policies and contracts are established, we believe roughly about midyear. To the second half of your question, what we've learned from the German audience is they don't go out and fundraise and look for these. They believe that the government does have a responsibility to take care of their citizens, and it will probably help us with an uptick on people that, okay, now I know how the system works. And an important thing is, if you look at the BG specifically, their annual report, and they did more rentals than anybody else, is specifically targeting making the process more transparent. That's the wording in their actual report and in the discussions we're having. So this, I think, will help the users and will be continued growth. I do think it translates to the U.S. The VA also has I think gained momentum, as we can see in the success we had, and the success we've had with the workman's comp groups. Kevin?

Just to add to Larry's comments, the one group we're talking with is a large social health insurance group, and we have 15 claims with them now, and a large part of that is the court case last summer that you referenced. And Larry referenced, again, the activity with the BG. 7 of the 10 rentals were with BG groups in Germany.

And then I was trying to dig in on the VA. How much visibility do you have there? Because it seems like -- I don't know if this is a pattern. It's like Q1 last year, they had a big order, and then they kind of tailed off. Q1 this year, they had another big order and it kind of tailed off again. Is that something we should think about as a pattern going forward or is it just you don't really have visibility?

It's more of a pattern of the study So last year they ordered the initial [indiscernible] units to get the first six centers up and running, which they ordered them in Q1 but they got them really up and running around midyear. And what you've seen this second order that we just got also was to get the remaining four centers. But the part that feeds into that and the part that was most important, frankly, for us to measure, is, okay, they've got 10 centers that'll be up and running now, are they effectively accruing patients? And they set their own goals as to when they did the study plan, and the 25 patients that have already been enrolled in only half the centers is, as they've characterized it, is exactly on schedule. So I think it's going to even out in its own way because the patients coming out of the study all become available in the SOP. Additionally, the VA does have some additional units budgeted. We can't tell the timing, when they're going to order for the further units for the co-op study, whether it's later this year or not. But they do have additional budgeted units. So I think this is the beginning of some quarter-to-quarter predictability, because the patients coming out of the study [indiscernible] a lot to us.

That makes sense. And then the last one for me is on the commercial side. It sounds like midyear this year is kind of building up to where you could get some more coverage contracts in Germany, some favorable decisions here in the U.S. In a perfect world, those all go well. How should you think about the ramp throughout the end of this year in the back half and then the 2018 -- or more specifically, what gives you confidence. What are your conversations with these commercial payers that gives you good feeling about them actually coming on boardmid-year this year.

Well, the depth of the discussions -- I'll start in Germany. They, to an extent, because of the court cases and because of the number of pending cases, we are far along in contract-type discussions to where we're reasonably confident that the contract will happen. We're not absolutely certain of the timing. But they have patients in line. To answer your question on implementation, I think there's two stages to it. Those that had been waiting in the system for them where they have pending claims, those will be shorter-term for us. As Kevin pointed out, one of them has 15 pending claims. I think you'll see those come up in the six-month-type cycle. But new patients will probably, between getting qualified and getting trained and actually getting their systems, will be greater than six months cycle, and will probably fall moreinto 2018. But it's making it predictable for both the patient, us, and eventually for you guys.

Yeah, and we said on the last call that we would expect the revenue to follow within 12 months after getting the claim, and I think that's important. As Larry pointed out, we've got some cases that are pending that would come through in the first six months. I think the other part of it is -- there are two important aspects of it. The first is getting patients that are covered under those groups in through the process that now they know that they have coverage. And I think the second aspect of that that's very important is as we have discussions with other groups. So getting these first coverage decisions in the U.S. and in Germany are important because then it sets a precedence for discussions with other groups as we're continuing to work on reimbursement and on the case-by- case processing that we're currently doing now.

Great, thank you for the question.

Your next question comes from the line of Matt Taylor from Barclays. Your line is open.

This is Xuyang Li, in for Matt. Can you talk about your manufacturing capacity and ability to meet demands from a [indiscernible] of orders from the VA or from broader reimbursement coverage?

We manufacture through a contract manufacturer, Sanmina, so our ability to ramp up is pretty quick. On any product like this, you have some longer lead times, but we're talking a couple months for a longer lead time. So as we build the business, we have the infrastructure in place to grow our manufacturing capacity.

Okay, great. On the balance sheet, any plans to strengthen the balance sheet, and maybe you can talk about priorities for cash usage in ongoing business?

I'll talk about priorities first. We really said that we're -- we've laid out our priorities for the year, and it's really focused on the commercialization efforts and reimbursement for the existing product and the R&D focus on our stroke product. That's really what we're focused on this year, and we'll prioritize those areas as we go forward. In terms of the balance sheet, we've said on the last call that we have sufficient resources to get us through our next key catalyst, and then we would look at all of our opportunities. We have an existing active ATM program, but we would also look at the markets, both equity and debt markets, to continue to fund the company. Q – Unidentified Analyst: Great, thanks for taking our question.

And we have a question from the line of Christian Moore from Jefferies. Your line is open.

Hey good morning, thanks for taking my question. Maybe the first one just on, I'm not sure if missed it, but if you gave the qualified lead number for the quarter, just in terms of tracking that.

I don't think we gave the number, but the number for the quarter was 138. One of the things that I want to point -- we haven't actually -- we'll provide that number for your benefit if you want. One of the things we actually haven't been including that, because as our business develops, we have a lot of patients in the queue, and it's really about getting more targeted in that area. We need a fewer number as we're building this business out, because there's more awareness of the device and of the industry.

Great, you have more than enough to work with in the queue already.

We do, but we want more. So a lot of our other focus has been key opinion leaders, particularly in Germany and the United States, because we believe having more physicians on the podium and also talking to their patients about why this should become the standard of care and why it is the standard of care for the right patients, we find that helping us qualify our leads and move the leads forward more effectively. So that has been a increased area of focus for us in getting these guys to -- I'll give an example of a couple of physicians that went out and presented at a workman's comp conference lately. That has resulted directly in some patients in some cases that we've seen. So those have been very for us as a way to move them through the system more effectively.

Great. Then maybe one on the rest of the world. Japan sales, obviously a very strong fourth quarter. In terms of the cadence for the year, is that kind of the expectation, that you'll have strong back-loaded years, or is it just going to be lumpy in terms of when rental and full sale units come in for that segment

It'll probably continue to be lumpy. We can't completely control the rest of world, although I would look at the activities we have. The insurance efforts are not limited only to Germany and the United States, which, those are the two we, as a company, are driving. For example, I cited what we've seen in Australia. The number of trained, waiting for ReWalk individuals in Australia, I don't know that we put that up publicly, but the distributor there has in excess of 30 trained individuals that hopefully can find a path to get these and the coverage, with the first by the NDIS, at least for training and now considering it for use, is important. And that translates to your question. I think all of those individuals will accept it. We can't tell when the Australian government, in that case, will cover. We've also seen activity in several other geographies as well that could result in boluses orders like we've seen in prior years, but the timing is -- lumpy is the characterization, I suppose.

Great, thanks. And then the last one just on the 28-unit order from the VA, 20 coming through this quarter. Will that basically come in the next quarter, or spread throughout the year? I'm probably expecting a similar cadence to what we saw in 2016, but just wanted to confirm that's how we should think about modeling that throughout the year.

Well, the order of 28 is that we ship 20 in Q1, we'll ship the other 8 in Q2. And then if there's other orders from the VA, we'll obviously ship them dependent on the date we get them, usually, in the quarter.

And then when you ship it, that's when you're booking them as placements, right?

Correct.

Great, thank you.

[Operator Instructions] Your next question comes from the line of Steven Lichtman from Oppenheimer. Your line is open.

This is Dennis in for Steve. First, it sounds like you remain confident on coverage coming proof from a national payer now more than one payer in the U.S. that you're speaking with, or could we see more than one in the U.S. near-term?

We are directly speaking with 2 currently at one level and then we're speaking to a lot of corporate and municipal groups in parallel. So there is more than one that we're speaking to with the same types of discussions.

Understood, Just to follow up there, is the positive movement from them being a payer exposed to a lot of case-by-case situations, or is it from them being a payer exposed to a data?

Primarily data. We've been fortunate in that groups that have good data, specifically the VA, have been willing to share that data, so they were able to examine not only the data we had from our clinical studies, but they were able to examine some of the data privately from the VA. So it gave them a good basis to consider, and that's where they stand today. They have spent a lot of time looking at it.

Great, thanks. And the last question just regarding data. Broadly speaking, any update on new data we could see over the next 12 to 18 months?

We have our current study ongoing. We would hope to do some interim reports. I think the more substantial data you will see from the VA, but that's not in our control. The randomized trial is right on target. I don't know when they will choose to publish and be public. certainly provided accrual information, which is what we cited today. When they're going to give more on results is, as I said, something we hope they do soon, because we believe it'll help us.

Great, thanks guys.

Your next question comes from the line of Kyle Rose from Canaccord. Your line is open.

. : , :

So the rent-to-purchase units, we had 10 rent-to-purchase units this quarter. There was 1 in the U.S., which was a VA unit, and then 9 in Europe. Then we also had 5 conversions this quarter, which, 2 were in the U.S. and 3 were in Europe.

Okay, great. And then wanted to talk a little bit on how you're seeing the marketplace, and just any competitive pressures, any increased competition, just what the focus is from a competitive standpoint. Any update there, either in the U.S. or globally.

Kyle, we see the industry developing, but at this point we into each other in terms of competitive components. We remain the most active in the United States on the personal sales, and we've either sold them in different places or we've been able to where we were targeting. Same in Germany. Generally, right now, the personal market is something that we have had the longest experience on with the sixth generation device, and that seems to have worked well for us. Relative to pricing, Kevin can address SAPs. We're really not getting any pressure there, either competitively or from even the payers, as I believe they see the value of what we're doing to their patients and their customers.

Yeah, just to reiterate, ASP, we have not seen any pushback from payers on ASP, and as I noted earlier, our gross margins reflect that. It's more of a geographic mix of more heavier weighted towards our direct market. But we really haven't had pushback on ASP.

Yeah, and in the United States, we've still remained -- there's only one product besides ours that's FDA-cleared for personal use, and similar in Europe. The other haven't made it into the two direct markets in any significant way. The other area that I've seen more activity is on stroke. Clearly, we've seen at least one of our competitors do a pretty good job and developing their structural exoskeleton of their and believe another one has begun a clinical trial. So you also see, I believe, all three of the major competitors reaching to the stroke opportunity because of the size of the need and the effectiveness of exoskeletons in helping those patients. We're approaching it somewhat differently in terms of our product. Ours is really, as we've described it, a non-structural system that is very lightweight. And importantly, for our point of view, we like the business model of this one because there's a capital to it, but also there's replacement components that we [indiscernible] will change over time, and there's some patient- components that really makes it a very economical business model. And if we take existing reimbursement codes, we would be able to present that to any laboratory and any clinic, and give them a model as to how it would be a profitable proposition for them to take that particular design. But the designs first [indiscernible] would benefit the patient, but economics was the second part of our consideration. So I do see a lot of activity in the stroke area.

Okay, great. I appreciate that the colour. And then just lastly, on the expectation for some reimbursement decisions from the larger players, you're talking about midyear. Was there a potential for us to see that [indiscernible] before the end of the Q2? I guess it's midyear, Q2, Q3. And then on that point, I know you're going to short of giving longer-term guidance, and that's not what I'm asking, but how do we think about the time to then, after a positive decision, the time to which we should start to see a meaningful move in momentum in topline revenues? Is it 6 months that it needs to play through, 9 months, 12 months? How do we think about that?

The first part, midyear, the main reason we've given that is based on the level of interaction and general discussions we've had with the insurers, but we don't control it, so it could be Q2, it could be Q3. But it's going to be seemingly at least decisions in that cycle based on the feedback the insurers have given us. If you can get them on the line, you can ask them the question instead of us, because I can't answer it, I'm sorry, more than that. Relative to time, once we get these coverage decisions, we believe that the patients that are already in line at these specific insurers will be shorter-term less than 6 months most of those should coming to our system, so some of that could affect current year, and we believe it will. But most new patients will probably fall well beyond the six months before the time they're qualified to get in the system, get trained, and the transaction is complete. So part of these policies will have a bigger impact in 2018 and 2019, obviously, as it becomes more routine.

Great, thank you very for taking the question.

We have no further questions at this time. I would like to turn the call back over to the presenters for closing remarks.

We appreciate everyone taking the time and interest, and we look forward to our Q2 call and our later calls this year as we can continue to discuss the progress we did today. Thank you, everybody.

This concludes today's conference call. Thank you for your participation. Have a wonderful day. You may now disconnect.